Rhythm Non Current Liabilities Total vs Total Liab Analysis

RYTM Stock

USD 52.80 1.75 3.21%

Rhythm Pharmaceuticals financial indicator trend analysis is much more than just breaking down Rhythm Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Rhythm Pharmaceuticals is a good investment. Please check the relationship between Rhythm Pharmaceuticals Non Current Liabilities Total and its Total Liab accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.

Non Current Liabilities Total vs Total Liab

Non Current Liabilities Total vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Rhythm Pharmaceuticals Non Current Liabilities Total account and Total Liab. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Rhythm Pharmaceuticals' Non Current Liabilities Total and Total Liab is 0.95. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Total Liab in the same time period over historical financial statements of Rhythm Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Rhythm Pharmaceuticals' Non Current Liabilities Total and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of Rhythm Pharmaceuticals are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Non Current Liabilities Total i.e., Rhythm Pharmaceuticals' Non Current Liabilities Total and Total Liab go up and down completely randomly.

Correlation Coefficient

0.95

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Non Current Liabilities Total

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Rhythm Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Rhythm Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.At this time, Rhythm Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 23rd of September 2024, Tax Provision is likely to grow to about 592.2 K, while Enterprise Value Over EBITDA is likely to drop (16.16).

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	1.2M	1.7M	1.8M	1.1M
Interest Income	447K	4.0M	13.2M	13.8M

Reconciled Depreciation Interest Income

Rhythm Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Net Tangible Assets	Capital Surpluse	Current Deferred Revenue	Other Assets
Total Assets		0.64	0.79	0.95	0.78	-0.8	-0.79	0.8	0.84	0.76	0.67	1.0	0.81	0.35	0.97	0.15	0.93	0.83	0.4	0.77	1.0	0.42	0.98	0.86	0.32	0.61
Other Current Liab	0.64		0.94	0.48	0.33	-0.5	-0.92	0.26	0.47	0.94	0.96	0.6	0.61	0.39	0.63	0.67	0.51	0.87	0.85	0.71	0.62	0.38	0.6	0.88	-0.23	0.98
Total Current Liabilities	0.79	0.94		0.67	0.61	-0.64	-0.97	0.52	0.64	0.95	0.92	0.77	0.72	0.42	0.78	0.53	0.72	0.97	0.77	0.89	0.78	0.41	0.77	0.97	-0.04	0.92
Total Stockholder Equity	0.95	0.48	0.67		0.82	-0.77	-0.65	0.84	0.8	0.61	0.51	0.97	0.69	0.11	0.95	-0.13	0.91	0.72	0.15	0.72	0.96	0.39	0.95	0.76	0.52	0.43
Property Plant And Equipment Net	0.78	0.33	0.61	0.82		-0.74	-0.62	0.79	0.78	0.53	0.38	0.79	0.65	0.26	0.72	-0.11	0.89	0.73	0.14	0.83	0.78	0.35	0.77	0.69	0.49	0.33
Net Debt	-0.8	-0.5	-0.64	-0.77	-0.74		0.74	-0.53	-0.97	-0.7	-0.62	-0.79	-0.66	-0.22	-0.66	-0.12	-0.82	-0.78	-0.32	-0.68	-0.79	-0.49	-0.74	-0.77	-0.18	-0.56
Retained Earnings	-0.79	-0.92	-0.97	-0.65	-0.62	0.74		-0.48	-0.72	-0.95	-0.9	-0.76	-0.75	-0.44	-0.73	-0.56	-0.72	-0.99	-0.78	-0.9	-0.77	-0.45	-0.76	-0.98	0.03	-0.92
Accounts Payable	0.8	0.26	0.52	0.84	0.79	-0.53	-0.48		0.6	0.36	0.23	0.83	0.56	0.26	0.84	-0.08	0.8	0.56	0.13	0.68	0.82	0.19	0.84	0.6	0.54	0.2
Cash	0.84	0.47	0.64	0.8	0.78	-0.97	-0.72	0.6		0.67	0.58	0.83	0.69	0.33	0.69	0.12	0.86	0.76	0.33	0.68	0.83	0.32	0.77	0.76	0.25	0.52
Non Current Assets Total	0.76	0.94	0.95	0.61	0.53	-0.7	-0.95	0.36	0.67		0.99	0.72	0.68	0.43	0.7	0.56	0.7	0.94	0.77	0.77	0.74	0.45	0.69	0.92	-0.18	0.96
Non Currrent Assets Other	0.67	0.96	0.92	0.51	0.38	-0.62	-0.9	0.23	0.58	0.99		0.63	0.61	0.4	0.62	0.62	0.58	0.88	0.8	0.67	0.65	0.43	0.6	0.87	-0.3	0.98
Cash And Short Term Investments	1.0	0.6	0.77	0.97	0.79	-0.79	-0.76	0.83	0.83	0.72	0.63		0.79	0.31	0.98	0.1	0.93	0.8	0.36	0.76	1.0	0.41	0.98	0.84	0.37	0.56
Common Stock Total Equity	0.81	0.61	0.72	0.69	0.65	-0.66	-0.75	0.56	0.69	0.68	0.61	0.79		0.42	0.76	0.32	0.72	0.76	0.5	0.72	0.8	0.61	0.8	0.77	0.18	0.59
Common Stock Shares Outstanding	0.35	0.39	0.42	0.11	0.26	-0.22	-0.44	0.26	0.33	0.43	0.4	0.31	0.42		0.27	0.65	0.45	0.42	0.65	0.35	0.33	-0.05	0.31	0.4	-0.37	0.46
Short Term Investments	0.97	0.63	0.78	0.95	0.72	-0.66	-0.73	0.84	0.69	0.7	0.62	0.98	0.76	0.27		0.11	0.87	0.77	0.37	0.75	0.97	0.41	0.98	0.83	0.37	0.56
Non Current Liabilities Total	0.15	0.67	0.53	-0.13	-0.11	-0.12	-0.56	-0.08	0.12	0.56	0.62	0.1	0.32	0.65	0.11		0.05	0.47	0.95	0.32	0.12	0.09	0.1	0.46	-0.64	0.72
Other Current Assets	0.93	0.51	0.72	0.91	0.89	-0.82	-0.72	0.8	0.86	0.7	0.58	0.93	0.72	0.45	0.87	0.05		0.79	0.3	0.76	0.93	0.36	0.9	0.79	0.32	0.52
Other Stockholder Equity	0.83	0.87	0.97	0.72	0.73	-0.78	-0.99	0.56	0.76	0.94	0.88	0.8	0.76	0.42	0.77	0.47	0.79		0.71	0.93	0.82	0.47	0.8	0.99	0.02	0.88
Total Liab	0.4	0.85	0.77	0.15	0.14	-0.32	-0.78	0.13	0.33	0.77	0.8	0.36	0.5	0.65	0.37	0.95	0.3	0.71		0.57	0.38	0.22	0.36	0.71	-0.49	0.88
Property Plant And Equipment Gross	0.77	0.71	0.89	0.72	0.83	-0.68	-0.9	0.68	0.68	0.77	0.67	0.76	0.72	0.35	0.75	0.32	0.76	0.93	0.57		0.77	0.41	0.79	0.92	0.23	0.69
Total Current Assets	1.0	0.62	0.78	0.96	0.78	-0.79	-0.77	0.82	0.83	0.74	0.65	1.0	0.8	0.33	0.97	0.12	0.93	0.82	0.38	0.77		0.41	0.99	0.85	0.35	0.59
Common Stock	0.42	0.38	0.41	0.39	0.35	-0.49	-0.45	0.19	0.32	0.45	0.43	0.41	0.61	-0.05	0.41	0.09	0.36	0.47	0.22	0.41	0.41		0.44	0.46	-0.04	0.39
Net Tangible Assets	0.98	0.6	0.77	0.95	0.77	-0.74	-0.76	0.84	0.77	0.69	0.6	0.98	0.8	0.31	0.98	0.1	0.9	0.8	0.36	0.79	0.99	0.44		0.85	0.38	0.55
Capital Surpluse	0.86	0.88	0.97	0.76	0.69	-0.77	-0.98	0.6	0.76	0.92	0.87	0.84	0.77	0.4	0.83	0.46	0.79	0.99	0.71	0.92	0.85	0.46	0.85		0.08	0.87
Current Deferred Revenue	0.32	-0.23	-0.04	0.52	0.49	-0.18	0.03	0.54	0.25	-0.18	-0.3	0.37	0.18	-0.37	0.37	-0.64	0.32	0.02	-0.49	0.23	0.35	-0.04	0.38	0.08		-0.35
Other Assets	0.61	0.98	0.92	0.43	0.33	-0.56	-0.92	0.2	0.52	0.96	0.98	0.56	0.59	0.46	0.56	0.72	0.52	0.88	0.88	0.69	0.59	0.39	0.55	0.87	-0.35

Click cells to compare fundamentals

Rhythm Pharmaceuticals Account Relationship Matchups

Rhythm Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	308.5M	187.1M	329.5M	382.5M	332.7M	186.9M
Other Current Liab	377K	180K	30.1M	32.9M	48.3M	50.7M
Total Current Liabilities	24.4M	18.0M	43.4M	39.8M	55.2M	58.0M
Total Stockholder Equity	281.0M	166.5M	284.2M	264.3M	169.8M	137.7M
Property Plant And Equipment Net	5.7M	5.0M	4.3M	3.4M	2.1M	2.4M
Net Debt	(58.7M)	(97.8M)	(56.7M)	(125.7M)	(58.8M)	(61.8M)
Retained Earnings	(325.3M)	(459.3M)	(528.9M)	(710.1M)	(894.7M)	(850.0M)
Accounts Payable	10.4M	4.9M	5.7M	4.8M	4.9M	4.4M
Cash	62.3M	100.9M	59.2M	127.7M	60.1M	50.8M
Non Current Assets Total	6.1M	5.4M	21.1M	28.2M	24.5M	25.7M
Cash And Short Term Investments	292.5M	172.8M	294.9M	333.3M	275.8M	169.6M
Common Stock Shares Outstanding	36.4M	44.1M	49.6M	52.1M	57.7M	39.3M
Short Term Investments	230.2M	71.9M	235.6M	205.6M	215.8M	142.5M
Liabilities And Stockholders Equity	308.5M	187.1M	329.5M	382.5M	332.7M	203.9M
Non Current Liabilities Total	3.1M	2.6M	1.9M	78.4M	107.8M	113.2M
Other Current Assets	9.9M	8.9M	12.5M	11.8M	6.7M	5.6M
Other Stockholder Equity	606.3M	625.8M	813.0M	974.4M	1.1B	1.1B
Total Liab	27.5M	20.5M	45.4M	118.2M	163.0M	171.1M
Property Plant And Equipment Gross	5.7M	5.0M	4.3M	3.4M	6.2M	6.5M
Total Current Assets	302.4M	181.7M	308.4M	354.2M	308.3M	178.6M
Accumulated Other Comprehensive Income	(752K)	49K	(1K)	(92K)	134K	140.7K
Net Tangible Assets	281.0M	166.5M	279.5M	256.4M	294.8M	163.0M
Capital Surpluse	606.3M	625.8M	813.0M	974.4M	1.1B	1.2B
Other Assets	403K	2.2M	12.1M	17.0M	19.5M	20.5M
Property Plant Equipment	5.7M	3.2M	2.8M	2.2M	2.5M	2.3M
Retained Earnings Total Equity	(325.3M)	(459.3M)	(528.9M)	(710.1M)	(639.1M)	(607.1M)
Net Invested Capital	281.0M	166.5M	284.2M	264.3M	169.8M	244.6M
Net Working Capital	278.0M	163.7M	265.0M	314.4M	253.1M	261.4M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Additional Information and Resources on Investing in Rhythm Stock

When determining whether Rhythm Pharmaceuticals is a strong investment it is important to analyze Rhythm Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rhythm Pharmaceuticals' future performance. For an informed investment choice regarding Rhythm Stock, refer to the following important reports:

How To Invest In Rhythm

Details

Is Rhythm Stock a good investment?

Details

What is Rhythm Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.

You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.35)

Revenue Per Share

1.709

Quarterly Revenue Growth

0.513

Return On Assets

(0.48)

Return On Equity

(1.43)

The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Rhythm Non Current Liabilities Total vs Total Liab Analysis

Non Current Liabilities Total vs Total Liab

Non Current Liabilities Total vs Total Liab Correlation Analysis

Correlation Coefficient

Non Current Liabilities Total

Total Liab

Rhythm Pharmaceuticals fundamental ratios Correlations

Rhythm Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Rhythm Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Additional Information and Resources on Investing in Rhythm Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Non Currrent Assets Other	+ 0.99	Non Current Assets Total
Capital Surpluse	+ 0.99	Other Stockholder Equity
Net Tangible Assets	+ 0.99	Total Current Assets

Other Stockholder Equity	- 0.99	Retained Earnings
Capital Surpluse	- 0.98	Retained Earnings
Cash	- 0.97	Net Debt
Retained Earnings	- 0.97	Total Current Liabilities
Non Current Assets Total	- 0.95	Retained Earnings
Other Assets	- 0.92	Retained Earnings